Introduction {#s1}
============

Increased risk of type 2 diabetes (T2D) is associated with abnormalities in sleep quantity ([@B1]) and quality ([@B1],[@B2]), circadian alignment ([@B3],[@B4]), and melatonin regulation ([@B5],[@B6]). A common variation at *MTNR1B* ([@B7],[@B8]) was identified by genome-wide association studies to associate with diabetes traits. The mechanism whereby these variants lead to elevated T2D risk is unknown.

*MTNR1B* is one of two high-affinity receptors for the pineal hormone melatonin, which is released exclusively at night and plays a role in glucose homeostasis ([@B6],[@B9]). In humans, the release of melatonin occurs concurrent with overnight fasting during sleep. Elevated melatonin levels during an oral glucose load during the day causes impaired glucose tolerance ([@B6],[@B10]). Common variants in *MTNR1B* associate with increased risk of T2D, fasting blood glucose (FBG) levels ([@B7],[@B8]), and lower glucose-stimulated insulin secretion in individuals without diabetes ([@B11]). Functional studies have established that *MTNR1B* rs10830963 is the likely causal variant ([@B12]). Strong independent association of rare, loss-of-function variants in *MTNR1B* with increased risk of T2D further implicates *MTNR1B* as the most likely causal gene in the region ([@B13]).

Although *MTNR1B* plays a role in glucose homeostasis (reviewed in refs. [@B14] and [@B15]), it is currently unknown how *MTNR1B* rs10830963 may alter its normal role in glucose metabolism. In this study, we explored the hypothesis that the association of rs10830963 with T2D may be mediated via effects on melatonin endocrinology, sleep timing/physiology, and/or the circadian system. Understanding these intermediate trait associations may lead to further insights into mechanisms by which risk variants influence glycemic traits and point toward new avenues of therapeutic intervention. We tested association of rs10830963 with sleep, circadian, and melatonin traits in two study populations with complementary strengths: *1*) intensive in-laboratory protocols (*n* = 58--96) with participants assessed for precise measures of circadian physiology, and *2*) cross-sectional studies (Candidate-gene Association Resource \[CARe\]) with sleep quantity, quality, and timing measures from questionnaires (*n* = 4,307--10,332), actigraphy (*n* = 1,513), and overnight polysomnography (PSG) (*n* = 3,021).

Research Design and Methods {#s2}
===========================

In-Laboratory Studies {#s3}
---------------------

### Study Participants {#s4}

Participants included 193 healthy individuals (a subset of 58--96 for whom measures of circadian physiology were available) from completed research studies in the Intensive Physiologic Monitoring Unit, Center for Clinical Investigation, Brigham and Women's Hospital from 2001--2011, as previously described, who donated a blood sample for genetic analysis ([@B16]). To promote a stable circadian rhythm, all participants maintained an 8-h sleep schedule of their choice at home for 1--3 weeks prior to admission. Compliance was verified with a sleep diary, call-ins, and wrist actigraphy. Participants also completed a morningness-eveningness questionnaire (MEQ) ([@B17]). The genetic sample collection and analyses were approved by the Partners HealthCare Human Research Committee. Separate informed consent was obtained for enrollment in the genetic studies.

### Circadian Phenotypes {#s5}

Of the 193 participants studied in the laboratory, a subset of 58--96 was assessed in intensive protocols with precise measures of endogenous circadian physiology. Measures of circadian rhythm timing (phase), magnitude (amplitude), length (period), and melatonin physiology were measured in the in-laboratory samples using hourly plasma melatonin concentrations and core body temperature (CBT) (1-min epochs) collected over a minimum of 24 h ([Supplementary Table 1](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db15-0999/-/DC1)). We used baseline data from individual studies in which subjects had undergone either a constant routine or posture protocol (*n* = 96) ([@B18]--[@B20]) or a forced desynchrony protocol (*n* = 63) ([@B21]--[@B23]) ([Supplementary Fig. 1*A*--*C*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db15-0999/-/DC1)). Melatonin phase measures collected included dim-light melatonin onset (DLMO) and dim-light melatonin offset (DLMOff) calculated as the time of the melatonin profile fitted curve at which levels crossed 25% of peak upward and downward, respectively; melatonin synthesis offset calculated from a linear model fitted to each melatonin profile ([@B24]); and the midpoint of melatonin calculated as the midpoint between DLMO and DLMOff \[DLMO + (DLMOff − DLMO)/2\]. Phase was also measured by CBT nadir, the time when the fitted circadian curve of CBT was at its minimum ([@B18]). To assess the difference between internal and external timing, phase angles were calculated as the time between sleep midpoint and DLMO, DLMOff, or CBT nadir. Circadian amplitude of melatonin and CBT were calculated as 50% of the difference between the minimum and peak of the fitted circadian curve. Measures of melatonin stability were calculated from a linear model fitted to each melatonin profile, generating plasma melatonin clearance rate and half-life. The duration of melatonin secretion was measured as the difference between DLMO and DLMOff. Sleep timing phenotypes included bedtime, wake time, midpoint of sleep, and sleep duration derived from 7 days of time-stamped call-ins during which subjects were required to maintain a self-selected but fixed 8-h sleep schedule prior to laboratory admission. Procedures for the determination of circadian phase, phase angle, amplitude, and period have been previously described ([@B17],[@B19],[@B21],[@B24]).

### Sample Genotyping {#s6}

DNA was extracted from whole blood using standard methods (Qiagen). All samples were genotyped for rs10830963 and 58 African American and Hispanic ancestry informative markers to test and correct for population stratification. Genotyping was performed using the Sequenom platform (Broad Institute, Cambridge, MA). Quality control steps excluded samples with \<60% call rate and single nucleotide polymorphisms (SNPs) with \<90% call rate, departure from Hardy-Weinberg equilibrium (*P* \< 10^−7^), or minor allele frequency \<1%. In-laboratory samples acquired since the original genotyping effort (*n* = 9) and samples that failed quality control in the previous round (*n* = 49) were whole-genome amplified and re-genotyped for all SNPs.

### Evaluation of Population Stratification {#s7}

The smartpca feature in EIGENSTRAT software ([@B25]) was used to calculate principal components after merging with HapMap 3 CEU, YRI, ASW, and CHB populations, and outliers 4 SD from the mean of the CEU population in the first three principal components were removed. Concordance between self-reported "non-Hispanic white" ancestry and included samples of European ancestry was 90.6%.

### Association Testing {#s8}

Genetic association analyses were performed in PLINK ([@B26]), using an additive genetic model and adjusting for age, sex, and five significant principal components that capture ancestry information. The significance threshold was set at *P* = 0.05. No correction was performed for multiple phenotypes tested.

CARe Study {#s9}
----------

### Study Participants {#s10}

Briefly, participants in the CARe study included \>40,000 multiethnic individuals from nine National Institute of Heart, Lung, and Blood Institute (NHLBI) cohorts with genotype and phenotype data, described by Musunuru et al. ([@B27]). We used data from up to 10,322 individuals of European ancestry from the Atherosclerosis Risk in Communities (ARIC) study ([@B28]), the Coronary Artery Risk Development in Young Adults (CARDIA) study ([@B29]), the Cardiovascular Health Study (CHS) ([@B30]), the Framingham Heart Study (FHS) ([@B31]), the Multi-Ethnic Study of Atherosclerosis (MESA) ([@B32]), and the ancillary Sleep Heart Health Study (SHHS) ([@B33]), selected based on the availability of data on genotyping, glycemic traits, sleep questionnaires, and PSG (*n* = 3,021). We also used data from the ancillary MESA Sleep Study conducted at visit 5 (*n* = 1,513), based on the availability of data on genotyping, wrist actigraphy ([@B34]), and glycemic traits.

### Sleep Phenotypes {#s11}

Self-reported sleep measures were assessed via questionnaires covering sleep behavior over the month leading up to the study in each parent cohort ([@B32],[@B33],[@B35]). Individual cohort questions ([Supplementary Table 2](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db15-0999/-/DC1)) were harmonized across CARe cohorts into the following self-reported sleep phenotypes: weekday and weekend bedtime; wake time; midpoint of sleep; weekday, weekend, and weekly sleep duration; average sleep latency; and the binary questions of difficulty falling asleep, wake after sleep onset, early morning awakenings, frequent napping, and excessive daytime sleepiness.

PSG sleep measures were available in the SHHS cohorts (*n* = 3,021). PSG was conducted during an unattended overnight home session as previously described ([@B36]). Participants were fitted with sensors by a certified technician, and data were captured overnight. Sleep stages were scored using guidelines described by Kales and Rechtschaffen ([@B37]). Total sleep time and total time in bed were available from the FHS component of SHHS (*n* = 556), and percentage of sleep time in each stage was available for all three SHHS cohorts (FHS, CHS, and ARIC, *n* = 3,021). The percentage of sleep time in each stage was computed by dividing time in the sleep stage by the recorded sleep time.

The MESA Sleep Study protocol included 7-day actigraphy (Actiwatch Spectrum, Philips Respironics, Murrysville, PA) together with sleep diaries and questionnaires (*n* = 1,513). Actigraphy data during 30-s intervals were scored as sleep or wake by Actiware-Sleep v.5.59 analysis software. Subject bedtime, sleep midpoint, and wake time from weekday, weekend, and weekly averaged data were calculated from actigraphy using the sleep log as upper and lower bounds. Sleep duration was defined as the average duration of sleep between sleep onset (sleep start time) and morning wakening (sleep end time) while in bed after "lights off."

### T2D Phenotypes {#s12}

Information on demographics, age, sex, and racial/ethnic group was obtained by questionnaire. Height, weight, and FBG levels were measured at visit 5. The use of diabetes medications was determined by questionnaire and from medication containers ([@B32]). T2D was defined as an FBG ≥7.0 mmol/L (126 mg/dL) or use of insulin/oral hypoglycemia medications.

### Sample Genotyping {#s13}

The ITMAT/Broad/CARE (IBC) array v2 genotype data included rs10830963 ([@B27],[@B38]). SNPs were clustered into genotypes using Illumina BeadStudio software. Quality control filters for SNPs and samples were applied separately within each cohort using PLINK ([@B26]). SNPs were excluded for Hardy-Weinberg equilibrium *P* \< 10^−7^ and call rates \<95% and samples for individual call rates \<90%, sex mismatch, and duplicate discordance. To control for relatedness, estimates of pairwise identity-by-descent were calculated, and individuals with values \>0.125 were pruned from the sample.

### Evaluation of Population Stratification {#s14}

Self-reported ethnicity was verified by multidimensional scaling analysis of identity-by-state distances as implemented in PLINK, including HapMap panels as reference standards. SNPs in linkage disequilibrium (*r^2^* \>0.3) were pruned and EIGENSTRAT was used to compute 10 principal components on the subset of individuals passing quality control for use as covariates in the regression analyses ([@B25]).

### Association Testing {#s15}

Power calculations were performed using Quanto in independent subjects using the gene-only setting ([@B39]). Linear and logistic regression analyses were performed in PLINK adjusting for age, sex, BMI, and principal components of ancestry ([@B26]). A fixed-effects, inverse-variance meta-analysis was performed in METAL ([@B40]). For primary analysis, significance threshold was set at *P =* 0.05 (as only one hypothesis was tested). No correction was performed for the multiple phenotypes tested. For interaction analyses, the significance was set at *P* \< 0.05, as only one hypothesis was tested. Interaction analysis adjusting for age, sex, and BMI was performed in PLINK ([@B26]). Interaction plots were generated in R using the effects package.

Results {#s16}
=======

Association With Later DLMOff and Longer Melatonin Duration in the In-Laboratory Studies {#s17}
----------------------------------------------------------------------------------------

Descriptive characteristics of the laboratory study population are shown in [Table 1](#T1){ref-type="table"}. We tested rs10830963 for association with sleep and circadian traits ([Table 2](#T2){ref-type="table"}). In the in-laboratory studies, we found significant associations between *MTNR1B* diabetes risk variant rs10830963G and timing of the melatonin rhythm: an allelic dose-dependent delayed DLMOff by 1 h and 22 min (β = 1.36 h, 95% CI 0.28--2.44, *N* = 95, *P* = 0.015, *r^2^* = 19%) and a longer duration of elevated melatonin levels by 41 min during constant routine protocols (defined as the difference between DLMO and DLMOff) (β = 41 min, 95% CI 4.2--78, *N* = 94, *P* = 0.032, *r^2^* = 2.5%). This association is driven by the delay in DLMOff, as we did not see an association with DLMO (*P =* 0.236) ([Table 2](#T2){ref-type="table"} and [Fig. 1](#F1){ref-type="fig"}).

###### 

Cohort characteristics

  ----------------------------------------------------------------------------------- ---------------
  In-laboratory studies                                                               
  * N*                                                                                198
   Females, *n* (%)[†](#t1n2){ref-type="table-fn"}                                    70 (35)
   Age, years[†](#t1n2){ref-type="table-fn"}                                          25.41 (9.58)
   Owl/lark questionnaire, numeric score (*n* = 193)[†](#t1n2){ref-type="table-fn"}   52.18 (12.15)
   Bedtime, clock time (*n* = 151)[\*](#t1n1){ref-type="table-fn"}                    23:49 (1.49)
   Sleep midpoint, clock time (*n* = 151)[\*](#t1n1){ref-type="table-fn"}             03:59 (1.41)
   Wake time, clock time (*n* = 151)[\*](#t1n1){ref-type="table-fn"}                  08:10 (1.46)
   Calculated sleep duration, h (*n* = 151)[\*](#t1n1){ref-type="table-fn"}           8.04 (0.13)
   Phase of DLMO, clock time (*n* = 96)                                               10:31 (1.86)
   Phase angle between melatonin onset and sleep midpoint, h (*n* = 93)               5.58 (1.09)
   Midpoint of melatonin secretion, clock time (*n* = 95)                             03:36 (1.82)
   Phase of DLMOff, clock time (*n* = 95)                                             08:38 (1.98)
   Phase angle between melatonin offset and sleep midpoint, h (*n* = 93)              4.53 (1.20)
   Phase of melatonin synthesis offset, clock time (*n* = 82)                         6:31 (1.95)
   Duration of melatonin secretion, h (*n* = 94)                                      10.11 (1.08)
   Plasma melatonin clearance rate, min^−1^ (*n* = 80)                                0.03 (0.02)
   Plasma melatonin clearance half-life, min (*n* = 80)                               34.17 (20.57)
   Circadian melatonin amplitude, pg/mL (*n* = 95)                                    38.30 (23.02)
   Circadian period of melatonin, h (*n* = 58)                                        24.17 (0.19)
   Phase of circadian CBT nadir, clock time (*n* = 90)                                04:59 (2.09)
   Phase angle between CBT nadir and sleep midpoint, h (*n* = 88)                     0.77 (1.37)
   Circadian CBT amplitude, °F (*n* = 89)[†](#t1n2){ref-type="table-fn"}              0.52 (0.15)
   Circadian period of CBT, h (*n* = 64)[†](#t1n2){ref-type="table-fn"}               24.15 (0.20)
  CARe study                                                                          
  * N*                                                                                10,332
   Females, *n* (%)                                                                   5,683 (55)
   Age, years                                                                         64.65 (12.49)
   BMI, kg/m^2^                                                                       27.34 (5.04)
   Self-report average weekly sleep duration, h (*n* = 8,380)                         7.24 (2.77)
   Self-report average weekday sleep duration, h (*n* = 6,508)                        7.1 (1.15)
   Self-report average weekend sleep duration, h (*n* = 4,517)                        7.48 (1.22)
   Calculated average weekly sleep duration, h (*n* = 4,476)\*\*                      7.48 (1.05)
   Calculated average weekday sleep duration, h (*n* = 4,505)\*\*                     7.39 (1.10)
   Calculated average weekend sleep duration, h (*n* = 4,488)\*\*                     7.72 (1.19)
   Bedtime, weekday, clock time (*n* = 4,542)                                         22:56 (1.05)
   Bedtime, weekend, clock time (*n* = 4,528)                                         23:11 (1.07)
   Sleep midpoint, weekday, clock time (*n* = 4,511)                                  02:32 (0.84)
   Sleep midpoint, weekend, clock time (*n* = 4,502)                                  02:55 (0.84)
   Wake time, weekday, clock time (*n* = 4,527)                                       06:19 (1.16)
   Wake time, weekend, clock time (*n* = 4,530)                                       06:54 (1.24)
   Sleep latency, min (*n* = 4,495)                                                   16.61 (17.14)
   Total sleep time, PSG measured, h (*n* = 556)                                      6.39 (0.97)
   Total time in bed, PSG measured, h (*n* = 556)                                     7.50 (0.84)
   REM sleep percent, PSG measured (*n* = 3,026)                                      19.51 (6.64)
   Stage 1 sleep percent, PSG measured (*n* = 3,026)                                  5.26 (3.87)
   Stage 2 sleep percent, PSG measured (*n* = 3,026)                                  57.02 (13.13)
   Stage 3/4 sleep percent, PSG measured (*n* = 3,026)                                18.22 (12.24)
   Self-reported cases, *n* (%)                                                       
    Frequent daytime sleepiness                                                       2,778 (26.97)
    Frequent difficulty falling asleep                                                3,455 (33.49)
    Frequent wake after sleep onset                                                   5,760 (55.79)
    Frequent early awakening                                                          3,747 (36.56)
    Frequent naps                                                                     2,415 (42.41)
  MESA                                                                                
  * N*                                                                                1,513
   Females, *n* (%)                                                                   853 (56)
   Age, years                                                                         69.18 (9.21)
   BMI, kg/m^2^                                                                       28.73 (5.63)
   Objectively measured bedtime, clock time                                           23:31 (1.40)
   Objectively measured sleep midpoint, clock time                                    03:07 (1.19)
   Objectively measured wake time, clock time                                         06:42 (1.38)
  ----------------------------------------------------------------------------------- ---------------

Data are shown as mean (SD) or *n* (%).

\*Measures were collected via call-ins during a 1-week schedule of 8 h of sleep prior to in-laboratory studies. All in-laboratory measures, except for those indicated with †, were from subjects on a study protocol with restricted 8-h time in bed.

\*\*Sleep duration was calculated from self-reported bedtime and wake time. REM, rapid eye movement.

###### 

*MTNR1B* rs10830963 association with sleep, circadian, and melatonin traits in the in-laboratory studies

                                                               *N*      β           SE          *P*
  ------------------------------------------------------------ -------- ----------- ----------- -----------
  Owl/lark questionnaire, numeric score                        193      −0.345      2.389       0.885
  Bedtime, clock time                                          151      30.36       19.38       0.119
  Sleep midpoint, clock time                                   151      31.8        19.38       0.103
  Wake time, clock time                                        151      33.12       19.5        0.091
  Calculated sleep duration, h                                 151      0.046       0.033       0.165
  Phase of DLMO, clock time                                    96       0.648       0.542       0.236
  Phase angle between melatonin onset and sleep midpoint, h    93       0.165       0.338       0.627
  Midpoint of melatonin secretion, clock time                  95       1.014       0.514       0.052
  Phase of DLMOff, clock time                                  **95**   **1.361**   **0.55**    **0.015**
  Phase angle between melatonin offset and sleep midpoint, h   93       0.45        0.382       0.242
  Phase of melatonin synthesis offset, clock time              82       1.047       0.624       0.097
  Duration of melatonin secretion, h                           **94**   **0.684**   **0.314**   **0.032**
  Plasma melatonin clearance rate, min^−1^                     80       −0.006      0.007       0.382
  Plasma melatonin clearance half-life, min                    80       4.753       7.048       0.502
  Circadian melatonin amplitude, pg/mL                         95       0.058       7.258       0.994
  Circadian period of melatonin, h                             57       0.01        0.067       0.885
  Phase of circadian CBT nadir, clock time                     90       0.627       0.575       0.279
  Phase angle between CBT nadir and sleep midpoint, h          88       −0.242      0.413       0.559
  Circadian CBT amplitude, °F                                  89       −0.027      0.042       0.521
  Circadian period of CBT, h                                   63       0.003       0.069       0.964

Results are from linear regression analysis in whites adjusted for age, sex, and five principal components of ancestry. Significant results are shown in boldface type, no correction was applied for multiple phenotypes. Allele frequency of rs10830963 in the in-laboratory studies was 0.32.

![Circadian phase of DLMOff and duration of elevated melatonin levels vary by *MTNR1B* genotype in the in-laboratory cohort. Adjusted mean and standard error shown by rs10830963 genotype (T2D risk allele G). *P* value derived from multiple linear regression tests between genotype and phenotype adjusted for age, sex, and principal components of ancestry. *A*: Circadian phase of DLMOff (*n* = 95, adjusted mean \[SE\] in clock time, CC 07:49 \[23 min\], CG 09:10 \[24 min\], and GG 10:32 \[35 min\]). *B*: Duration of melatonin production (*n* = 94, adjusted means \[SE\] in clock time, CC 9.70 h \[0.74\], CG 10.38 h \[1.15\], and GG 11.07 h \[1.21\]).](db150999f1){#F1}

We then asked if melatonin synthesis offset accounts for the relationship between rs10830963 and delayed DLMOff. A suggestive association of the risk allele with delayed melatonin synthesis offset (β = 1.05 h, 95% CI −0.17 to −2.28, *N* = 82, *P =* 0.097) was observed, and after conditioning on melatonin synthesis offset, the effect of rs10830963 on DLMOff was halved (β~conditional~ = 0.65 h, 95% CI −0.066 to 1.366, *P* = 0.079,*P*~ANOVA~ \< 0.001), suggesting partial mediation. Additional adjustment for season of study had no effect (data not shown).

We tested if chronotype or sleep timing contributes to the association between rs10830963 and DLMOff. We found significant mediation by sleep timing (bedtime 82.3%, *P* = 0.05; midpoint 84.4%, *P* = 0.04; wake time 85.9%, *P* = 0.05; chronotype (MEQ) 47.7%, *P* = 0.13), although a small portion of the effect is independent of sleep timing. The relationship between rs10830963 and melatonin duration is not mediated by sleep duration (*P* = 0.24).

Association With Glycemic Traits and Modification of T2D Risk by Sleep Timing in the CARe Study {#s18}
-----------------------------------------------------------------------------------------------

Descriptive characteristics of the CARe cohort are shown in [Table 1](#T1){ref-type="table"}. *MTNR1B* variant rs10830963 was significantly associated with T2D and FBG in the CARe study (T2D: odds ratio \[OR\] 1.08, 95% CI 1.01--1.16, *N* = 2,516 participants with diabetes/17,293 participants without diabetes, *P =* 0.01; FBG: β = 1.52 mmol/L, 95% CI 1.30--1.74, *N* = 17,252 participants without diabetes, *P =* 1.41 × 10^−41^).

No significant association was observed between *MTNR1B* rs10830963 and self-reported, 7-day actigraphy, or PSG measures of sleep timing, quality, or duration ([Table 3](#T3){ref-type="table"}). Notably, no comparable measures of melatonin secretion were available in the CARe cohorts, therefore our laboratory findings could not be evaluated in this study population.

###### 

*MTNR1B* rs10830963 association with sleep traits in CARe study

                                                  rs10830963G                                             
  ----------------------------------------------- ------------- ------------------- ---------- ---------- --------
  Bedtime, weekday, min                           4,359         −0.72               1.50       0.63       3.93
  Bedtime, weekend, min                           4,346         −0.84               1.56       0.60       4.2
  Sleep midpoint, weekday, min                    4,329         −0.78               1.20       0.51       3.3
  Sleep midpoint, weekend, min                    4,321         −0.66               1.20       0.58       3.3
  Wake time, weekday, min                         4,344         −1.08               1.62       0.51       4.5
  Wake time, weekend, min                         4,347         −0.78               1.80       0.66       4.8
  Self-report average weekly sleep duration, h    6,406         0.01                0.03       0.62       0.135
  Self-report average weekday sleep duration, h   6,321         0.02                0.02       0.45       0.065
  Self-report average weekend sleep duration, h   4,333         0.01                0.03       0.69       0.08
  Calculated average weekly sleep duration, h     4,295         0.00                0.03       0.99       0.07
  Calculated average weekday sleep duration, h    4,323         −0.01               0.03       0.85       0.07
  Calculated average weekend sleep duration, h    4,307         0.01                0.03       0.83       0.08
  REM sleep percent, PSG measured                 3,021         0.22                0.19       0.23       0.53
  Stage 1 sleep percent, PSG measured             **3,021**     **0.18**            **0.11**   **0.08**   0.31
  Stage 2 sleep percent, PSG measured             3,021         0.15                0.35       0.67       1.045
  Stage 3/4 sleep percent, PSG measured           **3,021**     **-0.55**           **0.32**   **0.08**   0.97
  Sleep latency, min                              6,316         0.99                0.01       0.38       1.15
  Objectively measured bedtime, min               1,513         −2.20               3.54       0.54       9.7
  Objectively measured sleep midpoint, min        1,513         −1.92               0.75       0.53       8.1
  Objectively measured wake time, min             1,513         −1.64               3.50       0.64       9.6
  Frequent difficulty falling asleep              9,846         1.01 (0.94--1.07)              0.88       1.052
  Frequent early awakening                        9,808         0.98 (0.92--1.05)              0.66       1.051
  Frequent daytime sleepiness                     9,977         0.98 (0.91--1.05)              0.65       1.05
  Frequent naps                                   6,457         1.06 (0.98--1.15)              0.15       1.0875
  Frequent wake after sleep onset                 9,855         0.97 (0.91--1.04)              0.43       1.064

Results are from linear or logistic regression analyses adjusting for age, sex, BMI, and ancestry. Suggestive results are shown in boldface type. Allele frequency was 0.27.

†Minimum detectable effect at 80% power, α = 0.05. REM, rapid eye movement.

However, given that sleep timing under a controlled sleep duration schedule largely mediated the association with DLMOff, we tested if rs10830963 association with T2D is modulated by sleep timing in the CARe study. If true, this would be consistent with the hypothesis that risk allele carriers with earlier wake times would be more likely to have elevated melatonin levels than noncarriers at times of T2D diagnostic testing and morning meal consumption, and this difference between genotypes would be less apparent in participants with later wake times. Objectively measured sleep timing (7-day actigraphy) significantly modified the effect of rs10830963 on T2D risk, such that earlier sleep timing in combination with the G allele carries an increased risk compared with later sleep timing (*N* = 1,513, bedtime *P*~interaction~ = 0.053, sleep midpoint *P*~int~ = 0.0176, wake time *P*~interaction~ = 0.024) ([Table 4](#T4){ref-type="table"} and [Fig. 2](#F2){ref-type="fig"}). In analyses of participants of European descent stratified by median bedtime, midpoint, and wake time, a significant association between rs10830963 genotype and T2D was seen in early sleep timing (bedtime \<23:12, *N* = 310, OR \[95% CI\] 1.48 \[1.01--2.18\], *P* = 0.044; midpoint \<02:58, *N* = 310, 1.80 \[1.00--3.22\], *P* = 0.0492; wake time \<06:41, *N* = 303, 1.88 \[1.04--3.40\], *P* = 0.035) but not in late sleep timing (bedtime ≥23:12, *N* = 310, 1.29 \[0.77--2.16\], *P* = 0.337; midpoint ≥02:58, *N* = 310, 1.34 \[0.79--2.29\], *P* = 0.277; wake time ≥06:41, *N* = 320, 1.25 \[0.74--2.13\], *P* = 0.406), independent of sleep duration. Thus, the effect of rs10830963 on risk of T2D may be modified by sleep timing, with risk allele carriers with earlier sleep timing at an increased risk.

###### 

Interaction results of rs10830963 with sleep timing on T2D risk

  Interaction phenotype                     Effect allele   Ethnicity       MAF        *N*         Early timing            Late timing                          *P*~interaction~
  ----------------------- ---- ------------ --------------- --------------- ---------- ----------- ----------------------- ----------------------- ------------ ------------------
  Bedtime                 11   rs10830963   G               Whites          0.26       619         1.48 (1.01--2.18)       1.29 (0.77--2.16)       0.1446       0.1907
                                                            Asians          0.42       167         2.38 (0.88--6.46)       0.70 (0.24--2.07)       0.2356       0.1170
                                                            Blacks          0.08       370         1.11 (0.56--2.19)       1.34 (0.60--3.00)       0.1867       0.9468
                                                            Hispanics       0.19       357         1.07 (0.57--2.04)       1.02 (0.55--1.89)       0.1490       0.2639
                                                            Meta-analysis   0.22       1,513       1.38 (1.03--1.83)       1.14 (0.81--1.60)       0.0846       0.0533
  Sleep midpoint          11   rs10830963   G               Whites          0.26       619         1.80 (1.00--3.22)       1.34 (0.79--2.29)       0.1783       0.0549
                                                            Asians          0.42       167         2.45 (0.89--6.70)       0.97 (0.37--2.49)       0.3007       0.0626
                                                            Blacks          0.08       370         1.07 (0.57--2.02)       1.02 (0.55--1.89)       0.2118       0.5954
                                                            Hispanics       0.19       357         1.30 (0.59--2.90)       1.05 (0.53--2.07)       0.1668       0.4665
                                                            Meta-analysis   **0.22**   **1,513**   **1.49 (1.05--2.13)**   **1.13 (0.81--1.57)**   **0.0996**   **0.0180**
  Wake time               11   rs10830963   G               Whites          **0.26**   **619**     **1.88 (1.04--3.40)**   **1.25 (0.74--2.13)**   **0.1720**   **0.0320**
                                                            Asians          0.42       167         2.09 (0.85--5.06)       0.84 (0.37--2.63)       0.2672       0.1616
                                                            Blacks          0.08       370         1.33 (0.61--2.94)       0.94 (0.47--1.87)       0.1808       0.3368
                                                            Hispanics       0.19       357         0.84 (0.44--1.60)       1.26 (0.67--2.37)       0.1490       0.8488
                                                            Meta-analysis   **0.22**   **1,513**   **1.32 (0.95--1.84)**   **1.13 (0.82--1.57)**   **0.0900**   **0.0290**

Results are from logistic regression with an interaction term. Model is adjusted for age, sex, and BMI. Wake time was measured by actigraphy across a minimum of 3 days. CHR, chromosome; MAF, minor G allele frequency. Odds of T2D are shown stratified by the median bedtime, midpoint, and wake time into "early" and "late." Significant results (*P* \< 0.05) are shown in boldface type.

![Sleep timing modifies the effect of *MTNR1B* variant rs10830963 on risk of T2D in MESA (*n* = 1,513). The effect of sleep timing on T2D risk is shown by rs10830963 genotype. The rs10830963G T2D risk allele is shown in red. Lines represent the genotype-specific linear regression of rs10830963 × 7-day actigraphy measured at bedtime (*A*), midpoint (*B*), and wake time (*C*) in 1,513 subjects of multiethnic ancestry, adjusted for age, sex, and BMI.](db150999f2){#F2}

Discussion {#s19}
==========

We hypothesized that a common T2D risk variant in *MTNR1B* would be associated with melatonin, sleep, or circadian traits. We found the *MTNR1B* diabetes risk variant (rs10830963G) was associated with a later melatonin offset and a longer duration of elevated melatonin levels in highly controlled laboratory studies. Furthermore, we demonstrated that the increased T2D risk in rs10830963G carriers is more pronounced in early sleep timing and almost absent in late sleep timing, in which an extended morning melatonin profile would be obscured by the later rise time. Thus, taken together, our data suggest that *MTNR1B* rs10830963G extends the duration of melatonin production later into the morning, and waking up earlier in the morning magnifies the diabetes risk with *MTNR1B* genotype.

The impact of *MTNR1B* rs10830963G on DLMOff is significantly mediated by sleep timing, suggesting that *MTNR1B* variation may influence DLMOff through changes in sleep timing or that *MTNR1B* variation may influence sleep timing through changes in the timing of the melatonin profile. No significant associations with other sleep and circadian traits were observed, consistent with previous studies of narrower scope showing no *MTNR1B* risk allele effect on self-reported sleep disturbances ([@B41],[@B42]). Although our observations must be regarded as preliminary due to the limited sample size with detailed circadian measures and melatonin profile, they collectively add new insights linking *MTNR1B* to T2D. Melatonin receptor 1B (known as Mel1B or MT2) is one of two *trans*-membrane receptors for melatonin, a hormone that acts as a signal for the biological night. *MTNR1B* rs10830963G allele carriers have been reported to show increased Mel1B receptor expression in the pancreatic β-cell ([@B11]). Melatonin signaling during the night, when diurnal humans are fasting, inhibits basal and glucose-stimulated insulin secretion ([@B5],[@B43],[@B44]). Delayed DLMOff and a longer duration of melatonin in risk allele carriers may result in an increased risk for food intake to coincide with elevated melatonin levels in the morning, leading to decreased glucose tolerance and possibly elevated diabetes risk. Consistently, risk allele carriers with earlier sleep timing have an increased T2D risk, possibly due to concomitant food intake and elevated melatonin levels in the morning. In addition to the adverse effects of an increase in melatonin levels into daytime, a reduction in nighttime melatonin signaling also appears to be deleterious. Reduced nighttime melatonin signaling, either by *MTNR1B* receptor rare loss-of-function variants ([@B13]) or reduced nighttime melatonin levels ([@B5]), is associated with an increased risk of T2D. Future studies are warranted to test causality and to assess how the impact of rs10830963G on melatonin offset and duration alters the proper timing and magnitude of basal and postprandial insulin secretion and glucose control.

The strength of our study comes from the depth and breadth of phenotypes available in our cohorts. The laboratory study was limited in size due to the nature of the intensive physiological studies required to obtain precise phenotypes. This sample is one of the largest of its kind and contains precisely measured endogenous circadian measures that require multiday studies under highly controlled laboratory conditions to assess endogenous circadian control of plasma melatonin and CBT. These results need to be interpreted in light of the biases of this study, however, as only young healthy subjects were studied and held to self-selected sleep schedules prior to the in-laboratory portion of the study (8-h sleep duration) that may not reflect biological preference. Although the sample size is limited, the phenotypes were measured in great depth, minimizing misclassification and maximizing specificity to biological processes of interest. Sleep timing in MESA is measured objectively across multiple days, minimizing phenotype measurement error. The sample size, however, is limited. In all future studies, it will also be important to measure melatonin levels at the time of glucose assessment in the morning by genotype.

The CARe study is a large well-powered study encompassing one of the largest epidemiological studies of sleep habits (SHHS) with self-reported and objective overnight PSG-measured sleep phenotypes. Notably, our study did not identify significant associations with the available measures of sleep quality or quantity in the CARe study, consistent with previous studies ([@B41],[@B42]). It is important to recognize, however, that the indices of sleep quality, duration, and timing available in these cohort studies likely are measured with modest-to-moderate error, and misclassification would attenuate any true associations. Previous studies demonstrated a 50% reduction in power associated with measurement error equivalent to one SD of the trait ([@B45]). This may even be true for PSG-measured phenotypes in the CARe study, where first-night effects influence sleep measures taken during a single unsupervised overnight PSG episode. This study establishes that diabetes risk variants in *MTNR1B* are unlikely to play a role in central sleep behaviors, and thus, future research should emphasize the evaluation of their role in peripheral tissues of relevance to T2D.

Given the clear and adverse effects of sleep disruption and circadian disruption on glucose control and diabetes risk, our new evidence linking sleep and the circadian-related *MTNR1B* gene variant with altered melatonin physiology and indicating how this might impact glucose control and diabetes risk is an important advance. Moving forward, the association of *MTNR1B* rs10830963 with melatonin rhythm phenotypes should be followed up with further in-depth mechanistic studies on a tissue level and phenotyping in individuals preselected based on genotypes of interest. In general, circadian metabolic assessments as well as targeted interventions (e.g., with light intervention or pharmacological doses of melatonin) may be useful strategies for probing the functional consequences of the variant on circadian rhythms, sleep physiology, and metabolism. Ultimately, this research could lead us toward new therapeutic interventions that reduce the impact of extended elevated melatonin levels into the morning perhaps via alterations to melatonin dynamics, melatonin-mediated insulin secretion, or timing of food intake.

This article contains Supplementary Data online at [http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db15-0999/-/DC1](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db15-0782/-/DC1).
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